166 related articles for article (PubMed ID: 20618995)
1. Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy.
Lerario A; Cogiamanian F; Marchesi C; Belicchi M; Bresolin N; Porretti L; Torrente Y
BMC Musculoskelet Disord; 2010 Jul; 11():157. PubMed ID: 20618995
[TBL] [Abstract][Full Text] [Related]
2. Dysferlinopathy: a clinical and histopathological study of 28 patients from India.
Nalini A; Gayathri N
Neurol India; 2008; 56(3):379-85; discussion 386-7. PubMed ID: 18974568
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes.
Nguyen K; Bassez G; Krahn M; Bernard R; Laforêt P; Labelle V; Urtizberea JA; Figarella-Branger D; Romero N; Attarian S; Leturcq F; Pouget J; Lévy N; Eymard B
Arch Neurol; 2007 Aug; 64(8):1176-82. PubMed ID: 17698709
[TBL] [Abstract][Full Text] [Related]
4. New aspects on patients affected by dysferlin deficient muscular dystrophy.
Klinge L; Aboumousa A; Eagle M; Hudson J; Sarkozy A; Vita G; Charlton R; Roberts M; Straub V; Barresi R; Lochmüller H; Bushby K
J Neurol Neurosurg Psychiatry; 2010 Sep; 81(9):946-53. PubMed ID: 19528035
[TBL] [Abstract][Full Text] [Related]
5. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.
Nagaraju K; Rawat R; Veszelovszky E; Thapliyal R; Kesari A; Sparks S; Raben N; Plotz P; Hoffman EP
Am J Pathol; 2008 Mar; 172(3):774-85. PubMed ID: 18276788
[TBL] [Abstract][Full Text] [Related]
6. Dysferlin deficiency treated like refractory polymyositis.
Vinit J; Samson M; Gaultier JB; Laquerriere A; Ollagnon E; Petiot P; Marie I; Levesque H; Rousset H
Clin Rheumatol; 2010 Jan; 29(1):103-6. PubMed ID: 19730931
[TBL] [Abstract][Full Text] [Related]
7. Dysferlin-deficient muscular dystrophy features amyloidosis.
Spuler S; Carl M; Zabojszcza J; Straub V; Bushby K; Moore SA; Bähring S; Wenzel K; Vinkemeier U; Rocken C
Ann Neurol; 2008 Mar; 63(3):323-8. PubMed ID: 18306167
[TBL] [Abstract][Full Text] [Related]
8. 4th Annual Dysferlin Conference 11-14 September 2010, Washington, USA.
Albrecht DE; Garg N; Rufibach LE; Williams BA; Monnier N; Hwang E; Mittal P
Neuromuscul Disord; 2011 Apr; 21(4):304-10. PubMed ID: 21339068
[No Abstract] [Full Text] [Related]
9. Lipid accumulation in dysferlin-deficient muscles.
Grounds MD; Terrill JR; Radley-Crabb HG; Robertson T; Papadimitriou J; Spuler S; Shavlakadze T
Am J Pathol; 2014 Jun; 184(6):1668-76. PubMed ID: 24685690
[TBL] [Abstract][Full Text] [Related]
10. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
11. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.
Rayavarapu S; Van der Meulen JH; Gordish-Dressman H; Hoffman EP; Nagaraju K; Knoblach SM
PLoS One; 2010 Sep; 5(9):e12981. PubMed ID: 20886045
[TBL] [Abstract][Full Text] [Related]
12. Challenges for the genetic screening in dysferlin deficiency--report of an instructive case and review of the literature.
Gal A; Siska E; Nagy Z; Karpati G; Molnar MJ
Clin Neuropathol; 2008; 27(5):289-94. PubMed ID: 18808059
[TBL] [Abstract][Full Text] [Related]
13. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle.
Rawat R; Cohen TV; Ampong B; Francia D; Henriques-Pons A; Hoffman EP; Nagaraju K
Am J Pathol; 2010 Jun; 176(6):2891-900. PubMed ID: 20413686
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice.
Dillingham BC; Benny Klimek ME; Gernapudi R; Rayavarapu S; Gallardo E; Van der Meulen JH; Jordan S; Ampong B; Gordish-Dressman H; Spurney CF; Nagaraju K
J Neurol Sci; 2015 Sep; 356(1-2):157-62. PubMed ID: 26119397
[TBL] [Abstract][Full Text] [Related]
15. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
16. [Amyloidosis in muscular dystrophy].
Carl M; Röcken C; Spuler S
Pathologe; 2009 May; 30(3):235-9. PubMed ID: 19326120
[TBL] [Abstract][Full Text] [Related]
17. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer.
Lostal W; Bartoli M; Bourg N; Roudaut C; Bentaïb A; Miyake K; Guerchet N; Fougerousse F; McNeil P; Richard I
Hum Mol Genet; 2010 May; 19(10):1897-907. PubMed ID: 20154340
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic overview of blood-based dysferlin protein assay for dysferlinopathies.
Ankala A; Nallamilli BR; Rufibach LE; Hwang E; Hegde MR
Muscle Nerve; 2014 Sep; 50(3):333-9. PubMed ID: 24488599
[TBL] [Abstract][Full Text] [Related]
19. Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset.
Kesari A; Fukuda M; Knoblach S; Bashir R; Nader GA; Rao D; Nagaraju K; Hoffman EP
Am J Pathol; 2008 Nov; 173(5):1476-87. PubMed ID: 18832576
[TBL] [Abstract][Full Text] [Related]
20. The absence of dysferlin induces the expression of functional connexin-based hemichannels in human myotubes.
Cea LA; Bevilacqua JA; Arriagada C; Cárdenas AM; Bigot A; Mouly V; Sáez JC; Caviedes P
BMC Cell Biol; 2016 May; 17 Suppl 1(Suppl 1):15. PubMed ID: 27229680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
